Latest & greatest articles for hepatitis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on hepatitis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on hepatitis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for hepatitis

181. Coding variants in PNPLA3 and TM6SF2 are risk factors for hepatic steatosis and elevated serum alanine aminotransferases caused by a glucagon receptor antagonist (PubMed)

Coding variants in PNPLA3 and TM6SF2 are risk factors for hepatic steatosis and elevated serum alanine aminotransferases caused by a glucagon receptor antagonist LY2409021 is a glucagon receptor antagonist that was associated with hepatic steatosis and elevated aminotransferases in phase 2 diabetes studies. We investigated the relationship between selected genetic variants and hepatic steatosis and elevated alanine aminotransferases (ALTs) associated with LY2409021. Patients participated in a 6 (...) -week placebo-controlled trial (I1R-MC-GLDI [GLDI], n = 246) and a 52-week placebo- and active comparator-controlled trial (I1R-MC-GLDJ [GLDJ], n = 158). GLDJ had endpoints at 6 months, including measures of hepatic fat fraction (HFF) by magnetic resonance imaging. The five genes tested were patatin-like phospholipase domain containing 3 (PNPLA3) (rs738409 and rs738491), transmembrane 6 superfamily member 2 (TM6SF2) (rs58542926), peroxisome proliferative activated receptor gamma coactivator 1 alpha

Full Text available with Trip Pro

2018 Hepatology communications

182. Consensus on Pegylated Interferon Alpha in Treatment of Chronic Hepatitis B (PubMed)

Consensus on Pegylated Interferon Alpha in Treatment of Chronic Hepatitis B 29577026 2018 11 14 2225-0719 6 1 2018 Mar 28 Journal of clinical and translational hepatology J Clin Transl Hepatol Consensus on Pegylated Interferon Alpha in Treatment of Chronic Hepatitis B. 1-10 10.14218/JCTH.2017.00073 Zhang Wenhong W Huashang Hospital of Fudan University, Shanghai, China. Zhang Dazhi D The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China. Dou Xiaoguang X Shengjing (...) Consensus Hepatitis B Interferons Therapy The authors have no conflict of interests related to this publication. 2017 11 08 2018 02 05 2018 02 09 2018 3 27 6 0 2018 3 27 6 0 2018 3 27 6 1 ppublish 29577026 10.14218/JCTH.2017.00073 JCTH.2017.00073 PMC5862993 Gut. 2013 Feb;62(2):290-8 22859496 Hepatology. 2009 Apr;49(4):1151-7 19115222 J Infect Dis. 2016 Mar 15;213(6):966-74 26582959 Gastroenterology. 2009 Dec;137(6):2002-9 19737568 Zhonghua Gan Zang Bing Za Zhi. 2010 Jul;18(7):495-7 20678437 J Viral

Full Text available with Trip Pro

2018 Journal of clinical and translational hepatology

183. HBsAg Loss with Peg-interferon Alfa-2a in Hepatitis B Patients with Partial Response to Nucleos(t)ide Analog: New Switch Study (PubMed)

HBsAg Loss with Peg-interferon Alfa-2a in Hepatitis B Patients with Partial Response to Nucleos(t)ide Analog: New Switch Study Background and Aims: Hepatitis B surface antigen (HBsAg) loss is seldom achieved with nucleos(t)ide analog (NA) therapy in chronic hepatitis B patients but may be enhanced by switching to finite pegylated-interferon (Peg-IFN) alfa-2a. We assessed HBsAg loss with 48- and 96-week Peg-IFN alfa-2a in chronic hepatitis B patients with partial response to a previous NA (...) . Methods: Hepatitis B e antigen (HBeAg)-positive patients who achieved HBeAg loss and hepatitis B virus DNA <200 IU/mL with previous adefovir, lamivudine or entecavir treatment were randomized 1:1 to receive Peg-IFN alfa-2a for 48 (n = 153) or 96 weeks (n = 150). The primary endpoint of this study was HBsAg loss at end of treatment. The ClinicalTrials.gov identifier is NCT01464281. Results: At the end of 48 and 96 weeks' treatment, 14.4% (22/153) and 20.7% (31/150) of patients, respectively, who

Full Text available with Trip Pro

2018 Journal of clinical and translational hepatology

184. Increase in hepatic and decrease in peripheral insulin clearance characterize abnormal temporal patterns of serum insulin in diabetic subjects (PubMed)

Increase in hepatic and decrease in peripheral insulin clearance characterize abnormal temporal patterns of serum insulin in diabetic subjects Insulin plays a central role in glucose homeostasis, and impairment of insulin action causes glucose intolerance and leads to type 2 diabetes mellitus (T2DM). A decrease in the transient peak and sustained increase of circulating insulin following an infusion of glucose accompany T2DM pathogenesis. However, the mechanism underlying this abnormal temporal (...) pattern of circulating insulin concentration remains unknown. Here we show that changes in opposite direction of hepatic and peripheral insulin clearance characterize this abnormal temporal pattern of circulating insulin concentration observed in T2DM. We developed a mathematical model using a hyperglycemic and hyperinsulinemic-euglycemic clamp in 111 subjects, including healthy normoglycemic and diabetic subjects. The hepatic and peripheral insulin clearance significantly increase and decrease

Full Text available with Trip Pro

2018 NPJ systems biology and applications

185. Tenofovir versus Placebo to Prevent Perinatal Transmission of Hepatitis B. (PubMed)

Tenofovir versus Placebo to Prevent Perinatal Transmission of Hepatitis B. Pregnant women with an elevated viral load of hepatitis B virus (HBV) have a risk of transmitting infection to their infants, despite the infants' receiving hepatitis B immune globulin.In this multicenter, double-blind clinical trial performed in Thailand, we randomly assigned hepatitis B e antigen (HBeAg)-positive pregnant women with an alanine aminotransferase level of 60 IU or less per liter to receive tenofovir (...) disoproxil fumarate (TDF) or placebo from 28 weeks of gestation to 2 months post partum. Infants received hepatitis B immune globulin at birth and hepatitis B vaccine at birth and at 1, 2, 4, and 6 months. The primary end point was a hepatitis B surface antigen (HBsAg)-positive status in the infant, confirmed by the HBV DNA level at 6 months of age. We calculated that a sample of 328 women would provide the trial with 90% power to detect a difference of at least 9 percentage points in the transmission

Full Text available with Trip Pro

2018 NEJM

186. Prolonged cenicriviroc therapy reduces hepatic fibrosis despite steatohepatitis in a diet‐induced mouse model of nonalcoholic steatohepatitis (PubMed)

Prolonged cenicriviroc therapy reduces hepatic fibrosis despite steatohepatitis in a diet‐induced mouse model of nonalcoholic steatohepatitis Nonalcoholic steatohepatitis (NASH) is a progressive liver disease projected to become the leading cause of cirrhosis and liver transplantation in the next decade. Cenicriviroc (CVC), a dual chemokine receptor 2 and 5 antagonist, prevents macrophage trafficking and is under clinical investigation for the treatment of human NASH fibrosis. We assessed (...) weeks based on histologic and molecular markers, mirroring observations in human NASH CVC trials. CVC also directly inhibited the profibrotic gene signature of transforming growth factor-β-stimulated primary mouse hepatic stellate cells in vitro. Conclusion: CVC is a novel therapeutic agent that is associated with reduced fibrosis despite ongoing steatohepatitis. Its ability to alter intrahepatic macrophage populations and inhibit profibrogenic genes in hepatic stellate cells in NASH livers may

Full Text available with Trip Pro

2018 Hepatology communications

187. Direct-Acting Antiviral Prophylaxis in Kidney Transplantation From Hepatitis C Virus-Infected Donors to Noninfected Recipients: An Open-Label Nonrandomized Trial. (PubMed)

Direct-Acting Antiviral Prophylaxis in Kidney Transplantation From Hepatitis C Virus-Infected Donors to Noninfected Recipients: An Open-Label Nonrandomized Trial. Given the high mortality rate for patients with end-stage kidney disease receiving dialysis and the efficacy and safety of hepatitis C virus (HCV) treatments, discarded kidneys from HCV-infected donors may be a neglected public health resource.To determine the tolerability and feasibility of using direct-acting antivirals (DAAs

Full Text available with Trip Pro

2018 Annals of Internal Medicine

188. Risk of hepatocellular carcinoma for patients treated with direct-acting antivirals: steps after hepatitis C virus eradication to achieve elimination (PubMed)

Risk of hepatocellular carcinoma for patients treated with direct-acting antivirals: steps after hepatitis C virus eradication to achieve elimination 29682622 2018 11 14 2415-1289 3 2018 Translational gastroenterology and hepatology Transl Gastroenterol Hepatol Risk of hepatocellular carcinoma for patients treated with direct-acting antivirals: steps after hepatitis C virus eradication to achieve elimination. 15 10.21037/tgh.2018.02.03 Lee Mei-Hsuan MH Institute of Clinical Medicine, National (...) Yang-Ming University, Taipei. eng Editorial Comment 2018 03 05 China Transl Gastroenterol Hepatol 101683450 2415-1289 Gastroenterology. 2017 Oct;153(4):996-1005.e1 28642197 Conflicts of Interest: The author has no conflicts of interest to declare. 2018 02 04 2018 02 19 2018 4 24 6 0 2018 4 24 6 0 2018 4 24 6 1 epublish 29682622 10.21037/tgh.2018.02.03 tgh-03-2018.02.03 PMC5897667 JAMA. 2012 Dec 26;308(24):2584-93 23268517 J Viral Hepat. 2018 Mar;25(3):228-235 29053909 Epidemiol Rev. 2015;37:131-43

Full Text available with Trip Pro

2018 Translational gastroenterology and hepatology

189. Sofosbuvir (Sovaldi) - for the treatment of chronic hepatitis C in adolescents

Sofosbuvir (Sovaldi) - for the treatment of chronic hepatitis C in adolescents Published 12 March 2018 Statement of Advice: sofosbuvir 400mg film-coated tablets (Sovaldi ® ) SMC No 1326/18 Gilead Sciences Ltd 9 February 2018 ADVICE: in the absence of a submission from the holder of the marketing authorisation sofosbuvir (Sovaldi ® ) is not recommended for use within NHS Scotland. Indication under review: In combination with other medicinal products for the treatment of chronic hepatitis C

2018 Scottish Medicines Consortium

190. Sofosbuvir?velpatasvir?voxilaprevir for treating chronic hepatitis C

Sofosbuvir?velpatasvir?voxilaprevir for treating chronic hepatitis C Sofosbuvir–v Sofosbuvir–velpatasvir–v elpatasvir–vo oxilapre xilaprevir for vir for treating chronic hepatitis C treating chronic hepatitis C T echnology appraisal guidance Published: 21 February 2018 nice.org.uk/guidance/ta507 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations (...) and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C (TA507) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 17Contents Contents 1 Recommendations

2018 National Institute for Health and Clinical Excellence - Technology Appraisals

191. Daclatasvir and sofosbuvir treatment of decompensated liver disease or post‐liver transplant hepatitis C virus recurrence in patients with advanced liver disease/cirrhosis in a real‐world cohort (PubMed)

Daclatasvir and sofosbuvir treatment of decompensated liver disease or post‐liver transplant hepatitis C virus recurrence in patients with advanced liver disease/cirrhosis in a real‐world cohort We report the findings of an early access program providing treatment for chronic hepatitis C virus infection (any genotype) with daclatasvir and sofosbuvir with/without ribavirin to patients with Child-Pugh class C cirrhosis or prior liver transplant recipients with recurrent hepatitis C virus

Full Text available with Trip Pro

2018 Hepatology communications

192. Changes in natural killer cells and exhausted memory regulatory T Cells with corticosteroid therapy in acute autoimmune hepatitis (PubMed)

Changes in natural killer cells and exhausted memory regulatory T Cells with corticosteroid therapy in acute autoimmune hepatitis Autoimmune hepatitis (AIH) is an immune-mediated liver disease currently treated by immunosuppressive medications with significant side effects. Thus, novel mechanistic treatments are greatly needed. We performed prospective deep immunophenotyping of blood immune cells in patients with acute AIH before and after corticosteroid therapy. Blood samples from 26 patients (...) . Conclusion: Activated effector NK cells, which correlate with biochemical measurements of hepatitis, and exhausted memory Tregs are increased in the blood of patients with treatment-naive AIH and decline with corticosteroid therapy. Inadequate regulation of NK cells by exhausted FOXP3pos Tregs may play a role in AIH pathogenesis and contribute to liver injury. (Hepatology Communications 2018;2:421-436).

Full Text available with Trip Pro

2018 Hepatology communications

193. New scoring classification for primary biliary cholangitis–autoimmune hepatitis overlap syndrome (PubMed)

New scoring classification for primary biliary cholangitis–autoimmune hepatitis overlap syndrome Autoimmune hepatitis (AIH) and primary biliary cholangitis (PBC) are two major immune-mediated chronic liver diseases. Overlap syndrome (OS) is diagnosed if patients have features of both AIH and PBC; however, there is no consensus on the definition or diagnostic criteria for OS. Here, we report a new scoring classification for OS and evaluate its usefulness. This new scoring classification (...) was developed by modifying the International Autoimmune Hepatitis Group classification by selecting histologic features of AIH and PBC along with modifications of biochemical and immunologic characteristics. We evaluated 272 patients with chronic liver disease, including 105 with AIH, 102 with PBC, and 65 with OS. The best performance for the diagnosis of OS was noted among patients with an overlap score of ≥21 who had a sensitivity of 98.5%, a specificity of 92.8%, a positive predictive value of 81.0

Full Text available with Trip Pro

2018 Hepatology communications

194. Occult Hepatitis C Virus Infection: A Review (PubMed)

Occult Hepatitis C Virus Infection: A Review Occult hepatitis C virus (HCV) infection (OCI), first described in 2004, is defined as the presence of HCV RNA in hepatocytes or peripheral blood mononuclear cells without detectable HCV RNA in the serum. Here, we aimed to review the epidemiology, diagnostic methods, clinical implications and potential management recommendations currently described in the literature, as well as the future directions for investigation of this entity. PubMed (...) and Cochrane databases were searched with combination of the following keywords: "occult", "hepatitis C virus", and "occult HCV infection". There are data to support OCI as a potential culprit in cryptogenic liver disease. There are also consistent data demonstrating the existence of OCI in specific populations, such as dialysis, human immunodeficiency virus-infected and hepatitis B virus-infected patients, and also in the general population. While the gold standard for diagnosis is liver biopsy

Full Text available with Trip Pro

2018 Journal of clinical and translational hepatology

195. Animal models for the study of hepatitis B virus infection (PubMed)

Animal models for the study of hepatitis B virus infection Even with an effective vaccine, an estimated 240 million people are chronically infected with hepatitis B virus (HBV) worldwide. Current antiviral therapies, including interferon and nucleot(s)ide analogues, rarely cure chronic hepatitis B. Animal models are very crucial for understanding the pathogenesis of chronic hepatitis B and developing new therapeutic drugs or strategies. HBV can only infect humans and chimpanzees, with the use

Full Text available with Trip Pro

2018 Zoological research

196. Sequencing of hepatitis C virus for detection of resistance to direct-acting antiviral therapy: A systematic review. (PubMed)

Sequencing of hepatitis C virus for detection of resistance to direct-acting antiviral therapy: A systematic review. The significance of the clinical impact of direct-acting antiviral (DAA) resistance-associated substitutions (RASs) in hepatitis C virus (HCV) on treatment failure is unclear. No standardized methods or guidelines for detection of DAA RASs in HCV exist. To facilitate further evaluations of the impact of DAA RASs in HCV, we conducted a systematic review of RAS sequencing protocols

Full Text available with Trip Pro

2018 Hepatology communications

197. Elucidating the differences in pathogenicity between hepatitis E virus genotypes: The quest continues (PubMed)

Elucidating the differences in pathogenicity between hepatitis E virus genotypes: The quest continues 29404519 2018 11 13 2471-254X 2 2 2018 02 Hepatology communications Hepatol Commun Elucidating the differences in pathogenicity between hepatitis E virus genotypes: The quest continues. 128-130 10.1002/hep4.1152 Vercouter Ann-Sofie AS Laboratory of Liver Infectious Diseases Ghent University Ghent Belgium. Meuleman Philip P Laboratory of Liver Infectious Diseases Ghent University Ghent Belgium

Full Text available with Trip Pro

2018 Hepatology communications

198. Core IM: 5 Pearls on Chronic Hepatitis B Part 2: Management

Core IM: 5 Pearls on Chronic Hepatitis B Part 2: Management Core IM: 5 Pearls on Chronic Hepatitis B Part 2: Management – Clinical Correlations Search Core IM: 5 Pearls on Chronic Hepatitis B Part 2: Management January 31, 2018 3 min read Podcast: | Subscribe: | By Amy Shen Tang MD, Marty Fried MD and Shreya P. Trivedi MD; Illustration by Michelle Lo, MD & Amy Ou, MD. Quiz yourself on the following 5 Pearls on Chronic Hepatitis B (HBV) Management Time Stamps What is the focused history (...) 5: HCC screening is based on risk factors such as family history of HCC, personal history of cirrhosis, ethnicity and sex of the patient with chronic hepatitis B. It starts at the time of diagnosis for African patients, age 40 for Asian men, age 50 for Asian women. Also, all patients w/ cirrhosis or a family hx of liver cancer should get routine screening. The AASLD recommends HCC screening with liver US every 6 months with or without serum alpha fetoprotein (AFP). References Terrault, N

2018 Clinical Correlations

199. [Ledipasvir/sofosbuvir (hepatitis C) - benefit assessment according to õ35a Social Code Book V]

[Ledipasvir/sofosbuvir (hepatitis C) - benefit assessment according to õ35a Social Code Book V] Ledipasvir/Sofosbuvir (chronische Hepatitis C bei Jugendlichen): nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A17-41 [Ledipasvir/sofosbuvir (hepatitis C) – benefit assessment according to §35a Social Code Book V] Ledipasvir/Sofosbuvir (chronische Hepatitis C bei Jugendlichen): nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A17-41 [Ledipasvir/sofosbuvir (hepatitis C (...) ) – benefit assessment according to §35a Social Code Book V] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Ledipasvir/Sofosbuvir (chronische Hepatitis C bei Jugendlichen): nutzenbewertung gemäß § 35a SGB V

2018 Health Technology Assessment (HTA) Database.

200. [Glecaprevir/pibrentasvir (chronic hepatitis C) - benefit assessment according to õ 35a Social Code Book V]

[Glecaprevir/pibrentasvir (chronic hepatitis C) - benefit assessment according to õ 35a Social Code Book V] Glecaprevir/Pibrentasvir (chronische hepatitis C): nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A17-34 [Glecaprevir/pibrentasvir (chronic hepatitis C) – benefit assessment according to § 35a Social Code Book V] Glecaprevir/Pibrentasvir (chronische hepatitis C): nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A17-34 [Glecaprevir/pibrentasvir (chronic hepatitis (...) C) – benefit assessment according to § 35a Social Code Book V] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Glecaprevir/Pibrentasvir (chronische hepatitis C): nutzenbewertung gemäß § 35a SGB V

2018 Health Technology Assessment (HTA) Database.